Close
Patheon

News Releases

  • 29 Jun 2017

    Investments in key service areas to meet growing customer demand

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical sector, today announced that it expects to invest approximately $45 million at key sites across its global network to meet growing customer demand for expanded service capabilities. “As outsourcing of Pharma development and manufacturing services continues to grow, our customers will need even moremore...
  • 08 Jun 2017

    Highlights:

    • 2Q 2017 revenue of $483 million
    • Net income from continuing operations of $28 million
      • Net income from continuing operations per diluted share of $0.19
    • 2Q 2017 Adjusted EBITDA of $94 million
    • Adjusted net income from continuing operations of $29 million
      • Adjusted net income from continuing operations per diluted share of $0.20
    DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017. Second quarter 2017 revenue was $483 million, compared to $469 million in the prior-year period, and second quarter 2017 adjusted EBITDA was $94 million, compared to $98 million in the prior-year period. Revenue for the first six months of fiscal 2017 was $more...
  • 15 May 2017

    -- Patheon Provides Entry into the Attractive, High-growth CDMO Market

    -- Combination Significantly Strengthens Thermo Fisher's Unique Value Proposition for Pharmaceutical and Biotech Customers by Adding Highly Complementary Services

    -- Creates Substantial Synergies and Positions Combined Company to Further Accelerate Growth

    -- Expected to be Immediately and Significantly Accretive to Adjusted Earnings Per Share (EPS)

    Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Patheon N.V. (NYSE: PTHN), a leading global provider of high-quality drug development and delivery solutions to the pharmaceutical and biopharma sectors, today announced that their boards of directors have approved Thermo Fisher's acquisition of Patheon. Thermo Fisher will commence a tender offer to acquire all of the issued and outstanding shares of Patheon for $35.00 per share in cash. The transactionmore...

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com

 
 

Media Contact

Mari Mansfield
4815 Emperor Blvd.,
Durham, NC 27703
(919) 226-3137
mari.mansfield@patheon.com